Target-Date Fund (TDF)

A Target-Date Fund (TDF) refers to a type of investment fund commonly offered in employer-sponsored 401(k) plans, designed to simplify retirement savings for participants. Also known as a "Lifecycle Fund" or "Target-Retirement Fund," a TDF is a professionally managed, diversified investment portfolio with an asset allocation strategy that automatically adjusts over time based on the target retirement date of the investor.

The primary objective of a Target-Date Fund is to provide employees with a hands-off approach to retirement investing, tailoring the asset allocation to become more conservative as the target retirement date approaches. This means that younger investors with longer investment horizons will have a higher proportion of equities, which tend to carry higher risk but offer greater growth potential. As employees age and approach retirement, the fund will gradually shift towards a higher allocation of fixed-income assets, such as bonds, to provide more stability and reduced volatility.

Example 1: Suppose an employee plans to retire in 2055. They would select a Target-Date Fund labeled as "2055 Fund" or something similar, which automatically adjusts its asset allocation over time to align with the individual's retirement year.

Example 2: Another employee planning to retire in 2040 would opt for a "2040 Fund." This fund will have a different asset allocation, with a greater emphasis on growth assets since they have a longer investment horizon compared to the first example.

Example 3: A seasoned employee closer to retirement, with a target retirement date of 2023, would select a "2023 Fund" that consists primarily of fixed-income investments to protect their accumulated savings and minimize exposure to market fluctuations as they approach retirement.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.